Pre-eclampsia is a serious pregnancy complication affecting 3–5% of UK pregnancies, characterised by new-onset high blood pressure after 20 weeks of gestation. Whilst pre-eclampsia can affect multiple organs including the liver, many women wonder whether it can cause fatty liver disease. Understanding the relationship between pre-eclampsia and liver complications is essential for expectant mothers and healthcare professionals alike. This article explores how pre-eclampsia affects the liver, clarifies the distinction between pre-eclampsia-related liver injury and true fatty liver disease, and outlines the warning signs, diagnosis, and treatment approaches used in the UK.
Summary: Pre-eclampsia does not directly cause fatty liver disease but instead causes hepatocellular injury through reduced blood flow and endothelial damage, which is fundamentally different from metabolic fat accumulation.
- Pre-eclampsia causes liver injury through ischaemia and vasospasm rather than fat deposition characteristic of fatty liver disease.
- Acute fatty liver of pregnancy (AFLP) is a separate rare condition involving true hepatic fat accumulation that can coexist with or mimic pre-eclampsia.
- HELLP syndrome (Haemolysis, Elevated Liver enzymes, Low Platelets) is a life-threatening variant affecting 10–20% of women with severe pre-eclampsia.
- Right upper quadrant or epigastric pain, persistent vomiting, and jaundice are key warning signs of liver involvement requiring urgent medical assessment.
- Liver function typically normalises completely within days to weeks following delivery, though pre-eclampsia indicates increased long-term cardiovascular risk.
- NICE guidelines recommend regular liver function testing in women with suspected or confirmed pre-eclampsia as part of comprehensive antenatal surveillance.
Table of Contents
Am I eligible for weight loss injections?
Find out whether you might be eligible!
Answer a few quick questions to see whether you may be suitable for prescription weight loss injections (like Wegovy® or Mounjaro®).
- No commitment — just a quick suitability check
- Takes about 1 minute to complete
Understanding Pre-eclampsia and Liver Complications
Pre-eclampsia is a serious pregnancy complication characterised by new-onset hypertension (blood pressure ≥140/90 mmHg) after 20 weeks of gestation, typically accompanied by proteinuria or evidence of maternal organ dysfunction. It affects approximately 3–5% of pregnancies in the UK and represents a leading cause of maternal and perinatal morbidity and mortality.
The liver is one of several organs that can be affected by pre-eclampsia. When the condition progresses, it may lead to a spectrum of hepatic complications ranging from mildly raised liver enzymes to severe liver dysfunction. The pathophysiology involves endothelial dysfunction and vasospasm, which reduce hepatic blood flow and can cause hepatocellular injury. This manifests as raised liver transaminases (ALT and AST) in a proportion of women with pre-eclampsia, though abnormal liver function tests alone do not diagnose pre-eclampsia without the context of hypertension and other features of organ dysfunction.
In severe cases, pre-eclampsia can progress to HELLP syndrome (Haemolysis, Elevated Liver enzymes, Low Platelets), a life-threatening variant affecting 10–20% of women with severe pre-eclampsia. HELLP syndrome represents a medical emergency requiring immediate specialist intervention. The liver complications associated with pre-eclampsia are distinct from primary liver diseases and usually resolve following delivery, though they require careful monitoring during pregnancy.
Understanding the relationship between pre-eclampsia and liver function is crucial for both healthcare professionals and expectant mothers. Early recognition of hepatic involvement allows for timely intervention, appropriate monitoring, and optimal timing of birth to prevent serious maternal and fetal complications. NICE guidelines (NG133: Hypertension in pregnancy) emphasise the importance of regular liver function testing in women with suspected or confirmed pre-eclampsia as part of comprehensive antenatal surveillance.
Can Pre-eclampsia Cause Fatty Liver?
Pre-eclampsia does not directly cause fatty liver disease in the traditional sense. The relationship between pre-eclampsia and hepatic fat accumulation is complex and often misunderstood. Pre-eclampsia primarily causes hepatocellular injury through ischaemia and endothelial damage rather than the metabolic fat deposition seen in typical fatty liver disease.
The liver changes associated with pre-eclampsia include:
-
Periportal haemorrhage and necrosis – caused by vasospasm and reduced hepatic perfusion
-
Subcapsular haematoma – in severe cases, potentially leading to liver rupture
-
Hepatocellular swelling – due to oedema and ischaemic injury
-
Fibrin deposition – within hepatic sinusoids
These pathological changes are fundamentally different from the microvesicular or macrovesicular steatosis (fat accumulation) characteristic of fatty liver disease. There is no evidence that pre-eclampsia causes the metabolic form of fatty liver disease (non-alcoholic fatty liver disease, NAFLD) that occurs outside pregnancy.
However, it is important to distinguish pre-eclampsia from acute fatty liver of pregnancy (AFLP), a separate and rare condition that does involve true hepatic steatosis. AFLP is linked to mitochondrial fatty acid oxidation defects (including fetal long-chain 3-hydroxyacyl-CoA dehydrogenase [LCHAD] deficiency) and can occasionally coexist with or be mistaken for severe pre-eclampsia, as both conditions may present in the third trimester with similar features including hypertension and proteinuria. The distinction is clinically significant because whilst both require delivery, AFLP involves specific metabolic derangements and carries different risks.
Women with pre-existing non-alcoholic fatty liver disease (NAFLD) may be at increased risk of developing pre-eclampsia, suggesting shared metabolic risk factors such as obesity, insulin resistance, and metabolic syndrome. This association reflects common underlying pathophysiology rather than one condition causing the other.
Acute Fatty Liver of Pregnancy vs Pre-eclampsia
Acute fatty liver of pregnancy (AFLP) and pre-eclampsia are distinct obstetric emergencies that can present with overlapping clinical features, making differentiation challenging but essential for appropriate management. AFLP is a rare condition occurring in approximately 1 in 7,000–20,000 pregnancies, typically in the third trimester, and involves microvesicular fatty infiltration of hepatocytes due to mitochondrial dysfunction.
Key distinguishing features include:
AFLP characteristics:
-
Severe nausea, vomiting, and abdominal pain (more prominent than in pre-eclampsia)
-
Jaundice and profound hypoglycaemia
-
Coagulopathy with elevated prothrombin time and low fibrinogen
-
Raised bilirubin (Swansea criterion >14 μmol/L; higher levels in severe disease)
-
Acute kidney injury with elevated creatinine
-
Encephalopathy in severe cases
-
Raised transaminases (variable; may be moderate or marked)
Pre-eclampsia/HELLP characteristics:
-
Hypertension and proteinuria (defining features)
-
Epigastric or right upper quadrant pain
-
Thrombocytopenia and haemolysis (in HELLP syndrome)
-
Raised transaminases (variable; can be very high)
-
Less prominent jaundice and hypoglycaemia
The Swansea criteria can assist in diagnosing AFLP, requiring six or more features including vomiting, abdominal pain, polydipsia/polyuria, encephalopathy, raised bilirubin (>14 μmol/L), hypoglycaemia (<4 mmol/L), raised uric acid (>340 μmol/L), leucocytosis (>11 × 10⁹/L), ascites or bright liver on ultrasound, raised transaminases (AST or ALT >42 IU/L), raised ammonia (>47 μmol/L), renal impairment (creatinine >150 μmol/L), and coagulopathy (PT >14 seconds or APTT >34 seconds).
Crucially, AFLP and pre-eclampsia can coexist. Both require immediate delivery as definitive treatment. The mode of birth (induction of labour or caesarean section) is individualised based on maternal and fetal condition, gestational age, coagulation status, and cervical favourability. Multidisciplinary care involving obstetricians, hepatologists, and anaesthetists is essential. Whilst pre-eclampsia-related liver dysfunction typically improves rapidly post-delivery, AFLP may initially worsen before recovery, sometimes requiring intensive care support and, rarely, liver transplantation.
Symptoms and Warning Signs to Watch For
Recognising the symptoms of liver involvement in pre-eclampsia is crucial for timely intervention and preventing serious complications. Women and healthcare providers should be vigilant for specific warning signs that indicate hepatic dysfunction requiring urgent medical assessment.
Key symptoms suggesting liver complications:
-
Right upper quadrant or epigastric pain – often described as severe, persistent pain beneath the ribs on the right side or in the upper central abdomen. This may indicate liver capsule distension, subcapsular haematoma, or hepatocellular injury
-
Nausea and vomiting – particularly when persistent or severe, especially in the third trimester
-
Malaise and general unwellness – feeling significantly unwell beyond typical pregnancy discomfort
-
Jaundice – yellowing of the skin or whites of the eyes (more common in AFLP but can occur in severe pre-eclampsia)
-
Unusual bruising or bleeding – suggesting coagulopathy from severe liver dysfunction
Additional pre-eclampsia warning signs:
-
Severe headaches that don't respond to paracetamol
-
Visual disturbances (flashing lights, blurred vision, seeing spots)
-
Sudden swelling of face, hands, or feet
-
Reduced fetal movements
-
Breathlessness or chest pain
-
Seizures (fits)
When to seek immediate medical attention:
Pregnant women experiencing severe abdominal pain, persistent vomiting, visual disturbances, severe headache, or feeling generally unwell should contact their midwife, maternity unit, or GP immediately. These symptoms warrant same-day assessment, as they may indicate progression to severe pre-eclampsia or HELLP syndrome.
Women should call 999 if they experience:
-
Seizures (fits)
-
Sudden severe breathlessness or chest pain
-
Collapse or loss of consciousness
Women diagnosed with pre-eclampsia should attend all scheduled monitoring appointments and report any new or worsening symptoms promptly. The NHS advises that if symptoms occur outside normal hours, women should contact their maternity unit directly or attend A&E if symptoms are severe. Early detection and intervention significantly improve outcomes for both mother and baby, making awareness of these warning signs essential for all pregnant women, particularly those with risk factors for pre-eclampsia.
Diagnosis and Treatment in the UK
In the UK, the diagnosis and management of pre-eclampsia with liver involvement follows NICE guidelines (NG133: Hypertension in pregnancy), which provide evidence-based recommendations for surveillance, investigation, and treatment.
Diagnostic investigations:
When pre-eclampsia is suspected, comprehensive assessment includes:
-
Blood pressure measurement – using validated equipment with appropriate cuff size
-
Urinalysis – for proteinuria (spot protein:creatinine ratio ≥30 mg/mmol or 24-hour collection ≥300 mg)
-
Blood tests – full blood count (platelets, haemoglobin), liver function tests (ALT, AST, bilirubin), renal function (creatinine), and coagulation screen if severe features present
-
Fetal assessment – ultrasound for growth, amniotic fluid volume, and umbilical artery Doppler studies
Liver function tests are essential for identifying hepatic involvement. Raised transaminases indicate hepatocellular injury, whilst thrombocytopenia (<100 × 10⁹/L) alongside raised liver enzymes suggests HELLP syndrome. Serial monitoring is crucial as liver dysfunction can progress rapidly. (Note: Serum uric acid is not used to diagnose pre-eclampsia per NICE guidance, though it may be measured in some settings.)
Treatment approaches:
Antihypertensive therapy is the mainstay of medical management to prevent complications such as stroke. NICE recommends:
-
Labetalol (first-line) – dosing is individualised and titrated by the clinician; typical starting doses are in the range of 100 mg twice daily, increased as needed
-
Nifedipine (modified-release) – if labetalol is contraindicated or ineffective
-
Methyldopa – alternative option, though slower onset
Dosing should be guided by the BNF, Summary of Product Characteristics (SmPC), and local protocols. ACE inhibitors, angiotensin receptor blockers (ARBs), and thiazide diuretics should be avoided in pregnancy due to risks to the fetus. Target blood pressure is typically 135/85 mmHg. Magnesium sulphate is administered for seizure prophylaxis in severe pre-eclampsia when birth is planned within 24 hours.
Definitive treatment is birth of the baby and placenta, which resolves the underlying pathophysiology. Timing depends on:
-
Severity of maternal condition
-
Gestational age
-
Fetal wellbeing
Women with severe features (including significant liver dysfunction) typically require birth after stabilisation, balancing maternal and fetal risks. The mode of birth (induction of labour or caesarean section) is individualised based on maternal and fetal condition, gestational age, coagulation status, and cervical favourability. A course of corticosteroids for fetal lung maturation is considered if birth is anticipated before 36 weeks. Management occurs in specialist maternity units with consultant-led care, and severe cases may require high-dependency or intensive care support.
Reporting suspected side effects: If you experience a suspected side effect from any medicine, you can report it via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk or by searching for 'Yellow Card' in the Google Play or Apple App Store.
Long-Term Liver Health After Pre-eclampsia
For most women, liver function normalises completely following delivery, typically within days to weeks. The hepatic changes associated with pre-eclampsia are generally reversible and usually do not cause permanent liver damage, though rare severe complications can have sequelae. Liver enzymes should be monitored postpartum as clinically indicated and usually return to normal ranges within a few weeks after birth.
However, women who have experienced pre-eclampsia, particularly with hepatic involvement, should be aware of potential long-term health implications:
Cardiovascular and metabolic risks:
Pre-eclampsia is now recognised as a marker of future cardiovascular disease risk. Women with a history of pre-eclampsia have:
-
2–4 times increased risk of developing hypertension later in life
-
Doubled risk of ischaemic heart disease and stroke
-
Increased risk of type 2 diabetes and metabolic syndrome
-
Potential increased risk of non-alcoholic fatty liver disease (NAFLD) due to shared metabolic risk factors
These associations reflect underlying endothelial dysfunction and metabolic abnormalities rather than direct liver damage from pre-eclampsia itself. There is no evidence that pre-eclampsia directly causes chronic liver disease, but the shared risk factors warrant attention.
Recommended follow-up:
NICE guidelines recommend that women who have had pre-eclampsia should:
-
Receive postnatal review at 6–8 weeks to check blood pressure and discuss future cardiovascular risk
-
Have a medical review by their GP to assess cardiovascular risk factors
-
Maintain a healthy lifestyle including balanced diet, regular exercise, maintaining healthy weight, and avoiding smoking
-
Undergo regular blood pressure monitoring
-
Consider cardiovascular risk assessment in midlife
Future pregnancy considerations:
Women with previous pre-eclampsia have a 15–25% recurrence risk in subsequent pregnancies. Prophylactic low-dose aspirin (75–150 mg daily) from 12 weeks of gestation is recommended for women with previous pre-eclampsia to reduce recurrence risk. Enhanced antenatal surveillance with regular blood pressure monitoring and urine protein checks is appropriate in subsequent pregnancies; liver function tests are performed if there is clinical concern for pre-eclampsia.
Maintaining awareness of these long-term health implications empowers women to engage proactively with preventive healthcare, optimising their long-term wellbeing following a pregnancy complicated by pre-eclampsia.
Frequently Asked Questions
Does pre-eclampsia damage your liver permanently?
For most women, liver function normalises completely within days to weeks following delivery, and pre-eclampsia does not cause permanent liver damage. Rare severe complications such as liver rupture can have lasting effects, but the hepatic changes associated with typical pre-eclampsia are reversible.
What is the difference between pre-eclampsia and acute fatty liver of pregnancy?
Pre-eclampsia causes liver injury through reduced blood flow and endothelial damage, whilst acute fatty liver of pregnancy (AFLP) involves true fat accumulation in liver cells due to mitochondrial dysfunction. AFLP is rarer (1 in 7,000–20,000 pregnancies), typically presents with severe vomiting, jaundice, and hypoglycaemia, and can occasionally coexist with pre-eclampsia.
Can I take labetalol if I have liver problems during pregnancy?
Labetalol is the first-line antihypertensive for pre-eclampsia in the UK, but its use requires careful consideration if you have significant liver dysfunction. Your obstetrician will assess your liver function tests and may adjust treatment or use alternative medications such as nifedipine if labetalol is contraindicated based on your individual clinical situation.
How do I know if my pre-eclampsia is affecting my liver?
Severe, persistent pain beneath your ribs on the right side or in your upper central abdomen is the key warning sign of liver involvement in pre-eclampsia. Other symptoms include persistent nausea and vomiting, jaundice (yellowing of skin or eyes), and unusual bruising, all of which require immediate medical assessment.
Will having pre-eclampsia increase my risk of fatty liver disease later in life?
Pre-eclampsia itself does not directly cause chronic fatty liver disease, but women with a history of pre-eclampsia have increased long-term risk of metabolic syndrome, type 2 diabetes, and cardiovascular disease. These shared metabolic risk factors may increase susceptibility to non-alcoholic fatty liver disease (NAFLD), making healthy lifestyle choices and regular health monitoring important.
What happens to my liver after I give birth if I had pre-eclampsia?
Liver function typically improves rapidly after delivery and usually returns to normal within days to weeks as the underlying pre-eclampsia resolves. Your healthcare team will monitor your liver enzymes postpartum as clinically indicated, and you should attend your 6–8 week postnatal review to ensure complete recovery.
The health-related content published on this site is based on credible scientific sources and is periodically reviewed to ensure accuracy and relevance. Although we aim to reflect the most current medical knowledge, the material is meant for general education and awareness only.
The information on this site is not a substitute for professional medical advice. For any health concerns, please speak with a qualified medical professional. By using this information, you acknowledge responsibility for any decisions made and understand we are not liable for any consequences that may result.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Heading 6
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Block quote
Ordered list
- Item 1
- Item 2
- Item 3
Unordered list
- Item A
- Item B
- Item C
Bold text
Emphasis
Superscript
Subscript
